Transforming growth factor-β-stimulated clone-22 is a negative-feedback regulator of Ras/Raf signaling: Implications for tumorigenesis

Cancer Science

Volumn 103, Issue 1, 2012, Pages 26-33

  Nakamura, Masaki ^a,b   Kitaura, Jiro ^a   Enomoto, Yutaka ^a   Lu, Yang ^a   Nishimura, Koutarou ^a   Isobe, Masamichi ^a   Ozaki, Katsutoshi ^a   Komeno, Yukiko ^a   Nakahara, Fumio ^a   Oki, Toshihiko ^a   Kume, Haruki ^b   Homma, Yukio ^b   Kitamura, Toshio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RAF PROTEIN; RAS PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; MALE; NONHUMAN; NUCLEAR EXPORT SIGNAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DIETHYLNITROSAMINE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOPRECIPITATION; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NIH 3T3 CELLS; PRECURSOR CELLS, B-LYMPHOID; RAF KINASES; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS;

EID: 84855486120     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02108.x     Document Type: Article

References (42)

1. Shibanuma M, Kuroki T, Nose K. Isolation of a gene encoding a putative leucine zipper structure that is induced by transforming growth factor beta 1 and other growth factors. J Biol Chem 1992; 267: 10219-24.
2. Hamil KG, Hall SH. Cloning of rat Sertoli cell follicle-stimulating hormone primary response complementary deoxyribonucleic acid: Regulation of TSC-22 gene expression. Endocrinology 1994; 134: 1205-12.
3. Jay P, Ji JW, Marsollier C, Taviaux S, Berge-Lefranc JL, Berta P. Cloning of the human homologue of the TGF beta-stimulated clone 22 gene. Biochem Biophys Res Commun 1996; 222: 821-6.
4. Fiol DF, Mak SK, Kültz D. Specific TSC22 domain transcripts are hypertonically induced and alternatively spliced to protect mouse kidney cells during osmotic stress. FEBS J 2007; 274: 109-24.
5. D'Adamio F, Zollo O, Moraca R et al. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity 1997; 7: 803-12.
6. Cannarile L, Zollo O, D'Adamio F et al. Cloning, chromosomal assignment and tissue distribution of human GILZ, a glucocorticoid hormone-induced gene. Cell Death Differ 2001; 8: 201-3.
7. Wu X, Yamada-Mabuchi M, Morris EJ et al. The Drosophila homolog of human tumor suppressor TSC-22 promotes cellular growth, proliferation, and survival. Proc Natl Acad Sci USA 2008; 105: 5414-9.
8. Treisman JE, Lai ZC, Rubin GM. Shortsighted acts in the decapentaplegic pathway in Drosophila eye development and has homology to a mouse TGF-beta-responsive gene. Development 1995; 121: 2835-45.
9. Hino S, Kawamata H, Uchida D et al. Nuclear translocation of TSC-22 (TGF-beta-stimulated clone-22) concomitant with apoptosis: TSC-22 as a putative transcriptional regulator. Biochem Biophys Res Commun 2000; 278: 659-64.
10. Kester HA, Blanchetot C, den Hertog J, van der Saag PT, van der Burg B. Transforming growth factor-beta-stimulated clone-22 is a member of a family of leucine zipper proteins that can homo- and heterodimerize and has transcriptional repressor activity. J Biol Chem 1999; 274: 27439-47.
11. Ohta S, Yanagihara K, Nagata K. Mechanism of apoptotic cell death of human gastric carcinoma cells mediated by transforming growth factor beta. Biochem J 1997; 324: 777-82.
12. Gupta RA, Sarraf P, Brockman JA et al. Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. J Biol Chem 2003; 278: 7431-8.
13. Lu Y, Kitaura J, Oki T et al. Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD. Leukemia 2007; 21: 2246-57.
14. Yu J, Ershler M, Yu L et al. TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia. Blood 2009; 113: 5558-67.
15. Nakashiro K, Kawamata H, Hino S et al. Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. Cancer Res 1998; 58: 549-55.
16. Shostak KO, Dmitrenko VV, Garifulin OM et al. Downregulation of putative tumor suppressor gene TSC-22 in human brain tumors. J Surg Oncol 2003; 82: 57-64.
17. Rentsch CA, Cecchini MG, Schwaninger R et al. Differential expression of TGF beta-stimulated clone 22 in normal prostate and prostate cancer. Int J Cancer 2006; 118: 899-906.
18. Hayakawa F, Towatari M, Kiyoi H et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000; 19: 624-31.
19. Mizuki M, Fenski R, Halfter H et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000; 96: 3907-14.
20. Murata K, Kumagai H, Kawashima T et al. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem 2003; 278: 32892-8.
21. Choudhary C, Schwäble J, Brandts C et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 2005; 106: 265-73.
22. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998; 273: 19925-8.
23. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-90.
24. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005; 6: 827-37.
25. Malumbres M, Barbacid M. Ras oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-65.
26. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-67.
27. Lauchle JO, Kim D, Le DT et al. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 2009; 461: 411-4.
28. Ayroldi E, Zollo O, Bastianelli A et al. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Invest 2007; 117: 1605-15.
29. Ayroldi E, Zollo O, Macchiarulo A, Di Marco B, Marchetti C, Riccardi C. Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol 2002; 22: 7929-41.
30. Samuels ML, Weber MJ, Bishop JM, McMahon M. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human Raf-1 protein kinase. Mol Cell Biol 1993; 13: 6241-52.
31. Terada K, Kaziro Y, Satoh T. Analysis of Ras-dependent signals that prevent caspase-3 activation and apoptosis induced by cytokine deprivation in hematopoietic cells. Biochem Biophys Res Commun 2000; 267: 449-55.
32. Onishi M, Nosaka T, Misawa K et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 1998; 18: 3871-9.
33. Kitamura T, Koshino Y, Shibata F et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol 2003; 11: 1007-14.
34. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000; 7: 1063-6.
35. Jaworski M, Buchmann A, Bauer P, Riess O, Schwarz M. B-Raf and Ha-Ras mutations in chemically induced mouse liver tumors. Oncogene 2005; 24: 1290-5.
36. Naugler WE, Sakurai T, Kim S et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-4.
37. Buchmann A, Karcier Z, Schmid B, Strathmann J, Schwarz M. Differential selection for B-raf and Ha-Ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis. Mutat Res 2008; 638: 66-74.
38. Kato N, Kitaura J, Doki N et al. Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models. Blood 2011; 117: 221-33.
39. Zambrowicz BP, Abuin A, Ramirez-Solis R et al. Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci USA 2003; 100: 14109-14.
40. Zambrowicz BP, Friedrich GA, Buxton EC, Lilleberg SL, Person C, Sands AT. Disruption and sequence identification of 2, 000 genes in mouse embryonic stem cells. Nature 1998; 392: 608-11.
41. Kalkuhl A, Troppmair J, Buchmann A et al. p21Ras downstream effectors are increased in activity or expression in mouse liver tumors but do not differ between Ras-mutated and Ras-wild-type lesions. Hepatology 1998; 27: 1081-8.
42. Hömig-Hölzel C, van Doorn R, Vogel C et al. Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence. EMBO J 2011; 30: 1753-65.